129 related articles for article (PubMed ID: 36780244)
1. Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis.
Kierkus J; Pesegova M; Klopocka M; Brankovic M; Kasai N; Efuni S; Kong J; Nakajima Y; Jordan C; Matsui T; Feagan BG; Strout V
Crohns Colitis 360; 2020 Oct; 2(4):otaa092. PubMed ID: 36780244
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis.
Kierkus J; Pesegova M; Klopocka M; Brankovic M; Kasai N; Efuni S; Kong J; Nakajima Y; Jordan C; Matsui T; Feagan BG; Strout V
Crohns Colitis 360; 2020 Jul; 2(3):otaa049. PubMed ID: 36776497
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis.
Furihata K; Ishiguro Y; Yoshimura N; Ito H; Katsushima S; Kaneko E; Shimabe M; Mukai M; Watanabe R; Morishige T
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):870-883. PubMed ID: 33512065
[TBL] [Abstract][Full Text] [Related]
4. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.
Papp KA; Gooderham MJ; Girard G; Raman M; Strout V
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):1324-1332. PubMed ID: 28556418
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis.
Nakagawa H; Iizuka H; Nemoto O; Shimabe M; Furukawa Y; Kikuta N; Ootaki K
J Dermatol Sci; 2020 Aug; 99(2):82-89. PubMed ID: 32651105
[TBL] [Abstract][Full Text] [Related]
6. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
[TBL] [Abstract][Full Text] [Related]
7. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
Sandborn WJ; Bhandari BR; Fogel R; Onken J; Yen E; Zhao X; Jiang Z; Ge D; Xin Y; Ye Z; French D; Silverman JA; Kanwar B; Subramanian GM; McHutchison JG; Lee SD; Shackelton LM; Pai RK; Levesque BG; Feagan BG
Aliment Pharmacol Ther; 2016 Jul; 44(2):157-69. PubMed ID: 27218676
[TBL] [Abstract][Full Text] [Related]
9. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
[TBL] [Abstract][Full Text] [Related]
10. Erratum: Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling.
Uda A; Eto Y; Li Y; Matsuda H; Demiya S; Watanabe T; Ota M; Iwakiri R; Igarashi A
Crohns Colitis 360; 2020 Apr; 2(2):otaa036. PubMed ID: 36780243
[TBL] [Abstract][Full Text] [Related]
11. Erratum:
Crohns Colitis 360; 2022 Oct; 4(4):otac049. PubMed ID: 36780258
[TBL] [Abstract][Full Text] [Related]
12. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
[No Abstract] [Full Text] [Related]
13. The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis).
Stüber E; Büschenfeld A; Lüttges J; Von Freier A; Arendt T; Fölsch UR
Eur J Clin Invest; 2000 Jul; 30(7):594-9. PubMed ID: 10886299
[TBL] [Abstract][Full Text] [Related]
14. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
15. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum: The Extracts of
Liang J; Liang J; Hao H; Lin H; Wang P; Wu Y; Jiang X; Fu C; Li Q; Ding P; Liu H; Xiong Q; Lai X; Zhou L; Chan S; Hou S
Front Immunol; 2020; 11():2092. PubMed ID: 33042122
[TBL] [Abstract][Full Text] [Related]
17. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2009 Jan; (1):CD007571. PubMed ID: 19160337
[TBL] [Abstract][Full Text] [Related]
18. Corrigendum to: Association between matrix Gla protein and ulcerative colitis according to DNA microarray data.
Dong XY; Wu MX; Zhang HM; Lyu H; Qian JM; Yang H
Gastroenterol Rep (Oxf); 2020 Jun; 8(3):252. PubMed ID: 32665857
[TBL] [Abstract][Full Text] [Related]
19. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS
Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
